Collins Stewart Reiterates a 'Buy' Rating on Alcon (ACL), Expects Novartis (NVS) to Acquire Additional Stake
Tweet Send to a Friend
Collins Stewart reiterates a 'Buy' rating on Alcon (NYSE: ACL). Price target increased from $96 to $108.
Collins ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Collins ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
